Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00181168|
Recruitment Status : Completed
First Posted : September 16, 2005
Results First Posted : November 2, 2018
Last Update Posted : November 2, 2018
|Condition or disease||Intervention/treatment||Phase|
|Thyroid Cancer||Drug: Euthyroid Group||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||63 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Utility of Recombinant Human Thyrotropin (rTSH) PET-CT Fusion Scanning to Identify Residual Well-differentiated Epithelial Thyroid Cancer|
|Study Start Date :||March 2001|
|Actual Primary Completion Date :||September 2003|
|Actual Study Completion Date :||September 2003|
Experimental: Euthyroid Group
Euthyroid Group: Subjects received rhTSH to prepare for radioiodine therapy.
Drug: Euthyroid Group
Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
Other Name: Recombinant Human TSH (rhTSH)
No Intervention: Hypothyroid Group
Hypothyroid Group: Thyroid hormone treatment was withheld before radioiodine therapy.
- PET-CT Fusion Scanning Sensitivity [ Time Frame: 21 Days ]PET/CT was performed before (basal PET) and 24-48 h after rhTSH administration (rhTSH-PET) in 63 patients (52 papillary and 11 follicular thyroid cancers). Images were blindly analyzed by two readers. The proposed treatment plan was prospectively assessed before basal PET, after basal PET, and again after rhTSH-PET.
- Increased Fluorodeoxyglucose (FDG) PET Standardized Uptake Value (SUV) After rTSH Specificity [ Time Frame: 21 Days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00181168
|United States, Maryland|
|Johns Hopkins Division of Endocrinology & Metabolism|
|Baltimore, Maryland, United States, 21287|
|United States, Texas|
|M.D. Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Institute Gustave Roussy|
|Principal Investigator:||Paul W Ladenson, MD||Johns Hopkins University|